Find Therapeutics Inc. receives support from Investissement Québec

Find Therapeutics recently secured CAD 11 million in guaranteed convertible debenture financing, led by Investissement Québec with participation from existing investors CTI Life Sciences Fund and adMare BioInnovations. The proceeds from this financing will be used to advance FTX-101, a First-in-Class remyelinating agent to restore vision in patients with chronic optic neuropathy (CON), in Phase 1 clinical trials. 

Founded in 2020 with CTI Life Sciences, adMare BioInnovations, and Domain Therapeutics, Find Therapeutics is dedicated to developing next-generation therapies to treat autoimmune inflammatory diseases.  

Bicha Ngo, President and CEO of Investissement Québec, stated, “Investissement Québec is proud to assist Find Therapeutics in its innovation and development efforts and to help fill a gap in the capital chain for young biotech businesses.” 

BCF is proud to have represented Find Therapeutics Inc. in this transaction, with a team led by our partner Annie Gauthier and composed of Laurence Babin, Gabriel Melançon, Luka Pavlovic, Eleonora Eusepi, Ashley Weiss, Kevin Vincelette, Nicolas St-Sauveur, Marc-André Godard, and Tina Glassman.